The on-site technical exchange meeting between Shandong Yinfeng Life Science Research Institute and Shandong University Qilu Hospital Orthopedics Department was successfully held
Release time:
2022-03-11
On the afternoon of March 8th, Jia Chunsheng, Vice President of Shandong Yinfeng Life Science Research Institute (our foundation's research unit), Liu Zhicheng, General Manager of Yinfeng Health Technology Service Co., Ltd., and Zang Chuanbao, Director of Cryogenic Medicine Research Center, were invited to participate in a hospital enterprise cooperation intention exchange meeting organized by the Orthopedics Department of Qilu Hospital, Shandong University. Liu Xinyu, Executive Deputy Director of Orthopedics and Director of Spinal Surgery at Qilu Hospital of Shandong University, Zhu Lei, Deputy Director of Orthopedics and Director of Hand and Foot Surgery, Cheng Lei, Deputy Director of Spinal Surgery, Xu Qingjia, Deputy Director of Hand and Foot Surgery, and more than 30 professional doctors and technical experts from the orthopedics department participated in this meeting.
At the meeting, the attending experts listened to the research progress of our hospital in the development of tissue engineering materials and medical devices, and discussed our cooperation intentions in the orthopedic application direction of our research products. They had in-depth exchanges on joint cartilage repair, spinal fusion repair, and other directions. Our collaborating expert, Professor Sun Wenquan from Shanghai University of Technology, specially attended this exchange meeting.
The R&D team of Yinfeng Low Temperature Medical Research Center has developed multiple forms of engineering materials using donated and clinically abandoned tissues of the same type, which have broad application prospects in filling and repairing various tissue defects. The orthopedic expert team of Qilu Hospital has shown strong interest in our hospital's related research and has reached an intention to further clinical cooperation.
According to incomplete statistics, there are currently 5-6 million patients with bone defects in China each year. However, the actual number of orthopedic surgeries using bone defect repair materials for treatment in China is only about 1.33 million per year. There is a strong demand for bone defect repair materials in clinical practice, and there is a huge gap in clinical demand that needs to be filled. We look forward to the rapid transformation and application of our research products in clinical practice, providing higher quality technical products and services for orthopedic patients.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
